JPRN-UMIN000000600
Completed
Phase 2
A prospective non-randomized phase II study to assess the efficacy of unrelated cord blood transplantation for adult unfavorable hematological malignancies (C-SHOT 0601) - A phase II study to assess the efficacy of unrelated cord blood transplantation for adult hematological malignancies (C-SHOT 0601)
agoya Blood and Marrow Transplantation Group0 sites60 target enrollmentFebruary 7, 2007
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Patients with acute myeloid leukemia/acute lymphocytic leukemia/myelodysplastic syndrome/chronic myelomonocytic leukemia categorized as high risk group
- Sponsor
- agoya Blood and Marrow Transplantation Group
- Enrollment
- 60
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •(1\)Positive for HIV antibody and/or HBs antigen and/or HCV antibody (2\)Graft manipulation such as T\-cell depletion (3\)history of administration of gemtuzumab ozogamicin within 6 month before transplantation (4\)Pregnant or during breast feeding (5\)Uncontrolled another neoplastic disease (6\)Uncontrolled active psychiatric disease (7\)Uncontrolled active infection (8\)Allergic history to drugs used in the conditioning regimen or GVHD prophylaxis regimen (9\)Patients suggested as ineligible by their attending physician
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
A prospective non-randomised phase II study to assess the safety and efficacy of melphalan combined with fludarabine as a reduced conditioning regimen for unrelated bone marrow transplantation for hematological malignancies (C-SHOT 0505)JPRN-C000000457agoya Blood and Marrow Transplantation Group54
Not yet recruiting
Phase 2
Study to evaluate the response to treatment with the medication pasireotide LAR and the expression of the substances AIP and miR-34a in patients with acromegalyAcromegalyE22.0RBR-29grfmFaculdade de Medicina - Universidade Federal do Rio de Janeiro (UFRJ)
Active, not recruiting
Not Applicable
A randomized trial to identify markers for personalized treatment in patients treated with bevacizumab and paclitaxel for advanced breast cancerAdvanced breast cancerTherapeutic area: Diseases [C] - Cancer [C04]EUCTR2012-003743-30-SEKarolinska University Hospital
Active, not recruiting
Not Applicable
A prospective randomized phase II study evaluating the monitoring of imatinib mesylate (Gliveec®) plasmatic through level in patients newly diagnosed with chronic phase chronic myelogenous leukaemia (CP-CML). - OPTIM IMATINIBChronic Phase Chronic myelogenous leukemia (CP CML)EUCTR2010-019568-35-FRCH VERSAILLES
Active, not recruiting
Phase 1
A study to assess the schemas of retreatment with Lutathera® in patients with new progression of intestinal well-differentiated neuroendocrine tumor.EUCTR2021-001306-30-FRInstitut Régional du Cancer de Montpellier146